{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:27:28Z","timestamp":1790767648914,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"name":"National Natural Science Foundation Council","award":["81671594"],"award-info":[{"award-number":["81671594"]}]},{"name":"National Natural Science Foundation Council","award":["2019309067"],"award-info":[{"award-number":["2019309067"]}]},{"name":"National Natural Science Foundation Council","award":["2020KY1040"],"award-info":[{"award-number":["2020KY1040"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.intimp.2020.106878","type":"journal-article","created":{"date-parts":[[2020,8,10]],"date-time":"2020-08-10T08:42:38Z","timestamp":1597048958000},"page":"106878","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["Relationships between increased circulating YKL-40, IL-6 and TNF-\u03b1 levels and phenotypes and disease activity of primary Sj\u00f6gren's syndrome"],"prefix":"10.1016","volume":"88","author":[{"given":"Caiqun","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhencheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaixing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.intimp.2020.106878_b0005","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMcp1702514","article-title":"Primary sj\u00f6gren's syndrome","volume":"378","author":"Mariette","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.intimp.2020.106878_b0010","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1002\/acr.21991","article-title":"European league against rheumatism sj\u00f6gren's syndrome disease activity index and european league against rheumatism sj\u00f6gren's syndrome patient-reported index: a complete picture of primary sj\u00f6gren's syndrome patients","volume":"65","author":"Seror","year":"2013","journal-title":"Arthritis. Care. Res (Hoboken)"},{"issue":"6","key":"10.1016\/j.intimp.2020.106878_b0015","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1136\/ard.2009.110619","article-title":"EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary sjogren's syndrome","volume":"69","author":"Seror","year":"2010","journal-title":"Ann. Rheum. Dis."},{"issue":"2","key":"10.1016\/j.intimp.2020.106878_b0020","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1136\/annrheumdis-2014-206008","article-title":"Defining disease activity states and clinically meaningful improvement in primary sj\u00f6gren's syndrome with EULAR primary sj\u00f6gren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI)","volume":"75","author":"Seror","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2020.106878_b0025","doi-asserted-by":"crossref","unstructured":"M. Prakash, et al., Diverse pathological implications of YKL-40: answers may lie in 'outside-in' signaling, Cell. Signal. 25 (7) (2013) 1567-1573, http:\/\/dx.doi.org\/ 10.1016\/j.cellsig.2013.03.016.","DOI":"10.1016\/j.cellsig.2013.03.016"},{"issue":"6","key":"10.1016\/j.intimp.2020.106878_b0030","first-page":"655","article-title":"Serum YKL-40 levels in rheumatoid arthritis: correlations between clinical and laborarory parameters","volume":"19","author":"Vos","year":"2001","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.intimp.2020.106878_b0035","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/215140","article-title":"YKL-40 as a novel factor associated with inflammation and catabolic mechanisms in osteoarthritic joints","volume":"2014","author":"V\u00e4\u00e4n\u00e4nen","year":"2014","journal-title":"Mediators. Inflamm."},{"issue":"1","key":"10.1016\/j.intimp.2020.106878_b0040","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1177\/0004563218786979","article-title":"Elevated serum YKL-40 correlates with clinical characteristics in patients with polymyositis or dermatomyositis","volume":"56","author":"Gao","year":"2019","journal-title":"Ann. Clin. Biochem."},{"key":"10.1016\/j.intimp.2020.106878_b0045","first-page":"1","article-title":"Serum levels of YKL-40 are increased in patients with psoriasis: a meta-analysis","volume":"22","author":"Kong","year":"2019","journal-title":"Postgrad. Med."},{"issue":"2","key":"10.1016\/j.intimp.2020.106878_b0050","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.atherosclerosis.2012.03.034","article-title":"YKL-40 is elevated in patients with peripheral arterial disease and diabetes or pre-diabetes","volume":"222","author":"Batinic","year":"2012","journal-title":"Atherosclerosis"},{"issue":"10","key":"10.1016\/j.intimp.2020.106878_b0055","doi-asserted-by":"crossref","first-page":"3103","DOI":"10.1002\/art.30465","article-title":"Chitinases in the salivary glands and circulation of patients with Sj\u00f6gren's syndrome: macrophage harbingers of disease severity","volume":"63","author":"Greenwell-Wild","year":"2011","journal-title":"Arthritis Rheum."},{"issue":"6","key":"10.1016\/j.intimp.2020.106878_b0060","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1136\/ard.61.6.554","article-title":"Classification criteria for Sj\u00f6gren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group","volume":"61","author":"Vitali","year":"2002","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.intimp.2020.106878_b0065","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/0030-4220(74)90160-1","article-title":"Minor Salivary Gland involvement in Sj\u00f6gren's syndrome","volume":"37","author":"Tarpley","year":"1974","journal-title":"Oral. Surg. Oral. Med. Oral. Pathol."},{"issue":"4","key":"10.1016\/j.intimp.2020.106878_b0070","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1080\/14397595.2016.1226470","article-title":"Elevated level of circulating CD4+Helios+FoxP3+ cells in primary Sjogren's syndrome patients","volume":"27","author":"Liu","year":"2017","journal-title":"Mod. Rheumatol."},{"issue":"3","key":"10.1016\/j.intimp.2020.106878_b0075","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/j.1365-2249.2009.03966.x","article-title":"Cells with regulatory function of the innate and adaptive immune system in primary Sj\u00f6gren's syndrome","volume":"157","author":"Szodoray","year":"2009","journal-title":"Clin. Exp. Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2020.106878_b0080","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1136\/ard.2009.115378","article-title":"Cytokines in Sjogren's syndrome: potential therapeutic targets","volume":"69","author":"Roescher","year":"2010","journal-title":"Ann. Rheum. Dis."},{"issue":"5","key":"10.1016\/j.intimp.2020.106878_b0085","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1080\/03009740902973821","article-title":"Health-related quality of life in patients with primary Sj\u00f6gren's syndrome: relationship with serum levels of proinflammatory cytokines","volume":"38","author":"Baturone","year":"2009","journal-title":"Scand. J. Rheumatol."},{"issue":"6","key":"10.1016\/j.intimp.2020.106878_b0090","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/j.0300-9475.2004.01432.x","article-title":"Circulating cytokines in primary Sj\u00f6gren's syndrome determined by a multiplex cytokine array system","volume":"59","author":"Szodoray","year":"2004","journal-title":"Scand. J. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2020.106878_b0095","first-page":"411","article-title":"Circulating levels of Th1\/Th2 cytokines in patients with primary Sj\u00f6gren's syndrome: correlation with clinical and immunological features","volume":"19","author":"Garc\u00edc-Carrasco","year":"2001","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.intimp.2020.106878_b0100","unstructured":"A. Alunno, et al., Discrepancy between subjective symptoms, objective measures and disease activity indexes: the lesson of primary Sj\u00f6gren's syndrome, Clin. Exp. Rheumatol. 36 Suppl 112 (3) (2018) 210-214."},{"key":"10.1016\/j.intimp.2020.106878_b0105","doi-asserted-by":"crossref","first-page":"409","DOI":"10.2147\/COPD.S152655","article-title":"The YKL-40 protein is a potential biomarker for COPD: a meta-analysis and systematic review","volume":"13","author":"Tong","year":"2018","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"issue":"2","key":"10.1016\/j.intimp.2020.106878_b0110","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1164\/rccm.201504-0760OC","article-title":"Increased YKL-40 and chitotriosidase in asthma and chronic obstructive pulmonary disease","volume":"193","author":"James","year":"2016","journal-title":"Am. J. Respir. Crit. Care. Med."},{"issue":"9","key":"10.1016\/j.intimp.2020.106878_b0115","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.3899\/jrheum.170373","article-title":"Clinical utility of YKL-40 in polymyositis\/dermatomyositis-associated interstitial lung disease","volume":"44","author":"Hozumi","year":"2017","journal-title":"J. Rheumatol."},{"issue":"2","key":"10.1016\/j.intimp.2020.106878_b0120","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1681\/ASN.2012060579","article-title":"Chitinase-like protein Brp-39\/YKL-40 modulates the renal response to ischemic injury and predicts delayed allograft function","volume":"24","author":"Schmidt","year":"2013","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.intimp.2020.106878_b0125","doi-asserted-by":"crossref","first-page":"95","DOI":"10.12659\/AOT.883844","article-title":"Correlation between serum YKL-40 (chitinase-3-like protein 1) level and proteinuria in renal transplant recipients","volume":"18","author":"Tatar","year":"2013","journal-title":"Ann. Transplant."},{"issue":"1","key":"10.1016\/j.intimp.2020.106878_b0130","first-page":"139","article-title":"Relationship between plasma YKL-40 levels and endothelial dysfunction in chronic kidney disease","volume":"49","author":"Keskin","year":"2019","journal-title":"Turk. J. Med. Sci."},{"issue":"1","key":"10.1016\/j.intimp.2020.106878_b0135","first-page":"3","article-title":"The role of chitin, chitinases, and chitinase-like proteins in pediatric lung diseases","volume":"2","author":"Mack","year":"2015","journal-title":"Mol. CellPediatr."},{"issue":"4","key":"10.1016\/j.intimp.2020.106878_b0140","first-page":"438","article-title":"Hematologic manifestations of primary Sj\u00f6gren's syndrome","volume":"24","author":"Manganelli","year":"2006","journal-title":"Clin. Exp. Rheumatol."},{"issue":"6","key":"10.1016\/j.intimp.2020.106878_b0145","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nri3843","article-title":"Fever and the thermal regulation of immunity: the immune system feels the heat","volume":"15","author":"Evans","year":"2015","journal-title":"Nat. Rev. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2020.106878_b0150","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jaut.2010.06.020","article-title":"Pro-inflammatory role of Anti-Ro\/SSA autoantibodies through the activation of Furin-TACE-amphiregulin axis","volume":"35","author":"Lisi","year":"2010","journal-title":"J. Autoimmun."},{"issue":"1","key":"10.1016\/j.intimp.2020.106878_b0155","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.cyto.2011.03.014","article-title":"IL-6, but not TNF-\u03b1, increases plasma YKL-40 in human subjects","volume":"55","author":"Nielsen","year":"2011","journal-title":"Cytokine"},{"key":"10.1016\/j.intimp.2020.106878_b0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2019.107394","article-title":"Roles of chitinase 3-like 1 in the development of cancer, neurodegenerative diseases, and inflammatory diseases","volume":"203","author":"Yeo","year":"2019","journal-title":"Pharmacol. Ther."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576920314508?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576920314508?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T21:48:33Z","timestamp":1762552113000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576920314508"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":32,"alternative-id":["S1567576920314508"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2020.106878","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Relationships between increased circulating YKL-40, IL-6 and TNF-\u03b1 levels and phenotypes and disease activity of primary Sj\u00f6gren's syndrome","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2020.106878","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106878"}}